DK3037538T3 - Fremgangsmåder og sammensætninger til specifik inhibering af beta-catenin ved hjælp af dobbeltstrenget rna - Google Patents

Fremgangsmåder og sammensætninger til specifik inhibering af beta-catenin ved hjælp af dobbeltstrenget rna Download PDF

Info

Publication number
DK3037538T3
DK3037538T3 DK16155285.6T DK16155285T DK3037538T3 DK 3037538 T3 DK3037538 T3 DK 3037538T3 DK 16155285 T DK16155285 T DK 16155285T DK 3037538 T3 DK3037538 T3 DK 3037538T3
Authority
DK
Denmark
Prior art keywords
rna
compositions
methods
specific inhibition
beta catenin
Prior art date
Application number
DK16155285.6T
Other languages
English (en)
Inventor
Bob Dale Brown
Henryk T Dudek
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3037538T3 publication Critical patent/DK3037538T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16155285.6T 2010-07-06 2011-07-01 Fremgangsmåder og sammensætninger til specifik inhibering af beta-catenin ved hjælp af dobbeltstrenget rna DK3037538T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36177610P 2010-07-06 2010-07-06
EP11804230.8A EP2591105B1 (en) 2010-07-06 2011-07-01 Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna

Publications (1)

Publication Number Publication Date
DK3037538T3 true DK3037538T3 (da) 2019-06-24

Family

ID=45441761

Family Applications (3)

Application Number Title Priority Date Filing Date
DK19171689.3T DK3587579T3 (da) 2010-07-06 2011-07-01 Fremgangsmåder og sammensætninger til specifik hæmning af beta-catenin ved hjælp af dobbeltstrenget rna
DK11804230.8T DK2591105T3 (da) 2010-07-06 2011-07-01 Fremgangsmåder og sammensætninger til specifik inhibering af beta-catenin ved hjælp af dobbeltstrenget rna
DK16155285.6T DK3037538T3 (da) 2010-07-06 2011-07-01 Fremgangsmåder og sammensætninger til specifik inhibering af beta-catenin ved hjælp af dobbeltstrenget rna

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK19171689.3T DK3587579T3 (da) 2010-07-06 2011-07-01 Fremgangsmåder og sammensætninger til specifik hæmning af beta-catenin ved hjælp af dobbeltstrenget rna
DK11804230.8T DK2591105T3 (da) 2010-07-06 2011-07-01 Fremgangsmåder og sammensætninger til specifik inhibering af beta-catenin ved hjælp af dobbeltstrenget rna

Country Status (9)

Country Link
US (5) US8815825B2 (da)
EP (4) EP2591105B1 (da)
JP (1) JP5976643B2 (da)
AU (1) AU2011276365B2 (da)
CA (2) CA2804214C (da)
DK (3) DK3587579T3 (da)
ES (3) ES2734743T3 (da)
PT (1) PT3587579T (da)
WO (1) WO2012006243A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2802658A2 (en) * 2012-01-09 2014-11-19 Novartis AG Rnai agents to treat beta-catenin related diseases
EP3265179A4 (en) * 2015-03-04 2018-07-18 The University of Chicago Beta-catenin inhibitors in cancer immunotherapy
AU2017232496B2 (en) 2016-03-16 2022-11-24 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
MA45469A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de bêta-caténine et leurs utilisations
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
US10407681B2 (en) * 2017-03-28 2019-09-10 The United States Of America, As Represented By The Secretary Of Agriculture Plant-mediated silencing of a fatty acid and retinoid binding protein in Pratylenchus penetrans
KR20190128692A (ko) 2017-03-28 2019-11-18 다이서나 파마수이티컬, 인크. 면역요법을 강화시키기 위한 베타-카테닌 발현의 감소
AU2018350983A1 (en) * 2017-10-18 2020-04-09 Dicerna Pharmaceuticals, Inc. Beta catenin nucleic acid inhibitor molecule
EP3714054A1 (en) * 2017-11-20 2020-09-30 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
JP2021509669A (ja) * 2018-01-05 2021-04-01 ディセルナ ファーマシューティカルズ インコーポレイテッド 免疫療法を強化するためのベータ−カテニン及びｉｄｏの発現の低減
CN112055597A (zh) * 2018-03-02 2020-12-08 迪克纳制药公司 用于治疗胆管缺乏相关病况的方法和组合物
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
JP7756166B2 (ja) * 2020-12-23 2025-10-17 イーライ リリー アンド カンパニー Ｒｎａ治療薬及びその使用方法
JP2024528701A (ja) * 2021-07-23 2024-07-30 アルナイラム ファーマシューティカルズ， インコーポレイテッド ベータカテニン（ＣＴＮＮＢ１）ｉＲＮＡ組成物およびその使用方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
WO1992007065A1 (en) 1990-10-12 1992-04-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Modified ribozymes
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US6326487B1 (en) 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US20030064384A1 (en) * 2001-04-02 2003-04-03 Mien-Chie Hung Beta-catenin is a strong and independent prognostic factor for cancer
US20060019917A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
CA2521464C (en) 2003-04-09 2013-02-05 Alnylam Pharmaceuticals, Inc. Irna conjugates
JP4912873B2 (ja) * 2003-04-09 2012-04-11 アルナイラム ファーマシューティカルズ， インコーポレイテッド ｉＲＮＡ複合体
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
US20090012018A1 (en) * 2004-09-13 2009-01-08 Matthias Hebrok Inhibition of pancretic cancer cell growth
US20090176725A1 (en) * 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
US20090018097A1 (en) 2005-09-02 2009-01-15 Mdrna, Inc Modification of double-stranded ribonucleic acid molecules
WO2007031091A2 (en) * 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
WO2008109369A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
WO2008132234A2 (en) * 2007-05-01 2008-11-06 Santaris Pharma A/S Rna antagonist compounds for the modulation of beta-catenin
WO2008156661A2 (en) * 2007-06-15 2008-12-24 Beth Israel Deaconess Medical Center BACTERIAL MEDIATED TNF-α GENE SILENCING
TWI455944B (zh) * 2008-07-01 2014-10-11 Daiichi Sankyo Co Ltd 雙股多核苷酸
JP2012005734A (ja) 2010-06-28 2012-01-12 Panasonic Corp 電気掃除機用吸込具及びそれを備えた電気掃除機
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)

Also Published As

Publication number Publication date
WO2012006243A3 (en) 2012-06-14
EP2591105A2 (en) 2013-05-15
JP2013534425A (ja) 2013-09-05
US20160053263A1 (en) 2016-02-25
EP3587579A1 (en) 2020-01-01
DK3587579T3 (da) 2021-04-26
ES2734743T3 (es) 2019-12-11
US10612023B2 (en) 2020-04-07
DK2591105T3 (da) 2017-07-31
US20190002879A1 (en) 2019-01-03
CA2804214C (en) 2022-04-12
JP5976643B2 (ja) 2016-08-24
US9428752B2 (en) 2016-08-30
US9243244B2 (en) 2016-01-26
HK1227054A1 (en) 2017-10-13
ES2873893T3 (es) 2021-11-04
US10072263B2 (en) 2018-09-11
EP3037538B1 (en) 2019-05-01
EP3854874A1 (en) 2021-07-28
US20160186176A1 (en) 2016-06-30
EP3037538A1 (en) 2016-06-29
US20140288292A1 (en) 2014-09-25
CA2804214A1 (en) 2012-01-12
US8815825B2 (en) 2014-08-26
EP2591105B1 (en) 2017-05-31
EP2591105A4 (en) 2014-09-10
AU2011276365A1 (en) 2013-01-10
ES2635388T3 (es) 2017-10-03
WO2012006243A2 (en) 2012-01-12
CA3146952A1 (en) 2012-01-12
US20130109740A1 (en) 2013-05-02
PT3587579T (pt) 2021-05-24
EP3587579B1 (en) 2021-03-03
AU2011276365B2 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
CY2019040I1 (el) Aνti-il-23 αντισωματα
DK2504451T3 (da) Fremgangsmåder til at forudsige det kliniske forløb af cancer
DK3587579T3 (da) Fremgangsmåder og sammensætninger til specifik hæmning af beta-catenin ved hjælp af dobbeltstrenget rna
DK3329775T3 (da) Fremgangsmåder til syntese af diarylthiohydantoin- og diarylhydantoinforbindelser
DK3702371T5 (da) Anti-FGFR3-antistoffer og fremgangsmåder ved anvendelse af disse
DK2533761T3 (da) Fremgangsmåder og sammensætninger til fremstilling af aerosoler
DK3222716T3 (da) Sammensætninger til saccharificering af cellulosemateriale
DK2627656T3 (da) Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
SG10201506492PA (en) Improved antibodies of the class igg4
DK2593449T3 (da) Fremgangsmåde til syntese af benzothiadiazolforbindelse
DK2658965T3 (da) Fremgangsmåde til fremstilling af inducerede pluripotente stamceller og differentierede celler
ME03378B (me) Protutijela protiv dkk-1
DK2526425T3 (da) Fremgangsmåde til diagnosticering af endometriel receptivitet
DK3141548T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af azaindoler
IL250367A0 (en) Compounds, compositions and methods useful for cholesterol mobilisation
DK2307445T3 (da) Fremgangsmåde til fremstilling af caspofungin og mellemforbindelser heraf
DK2392548T3 (da) Fremgangsmåde til fremstilling af en amorf siliciumdioxid-sammensætning og beslægtet amorf siliciumdioxid-aluminiumoxid-samensætning
DK2582673T3 (da) Fremgangsmåde til fremstilling af 2,2-difluorethylamin-derivater ved hjælp af alkylering med 2,2-difluor-1-halogenethaner
DK2683371T3 (da) Forbindelser og fremgangsmåder til forbedring af forringet endogen fibrinolyse ved anvendelse af histondeacetylasehæmmere
DK2462098T3 (da) Fremgangsmåde til fremstillingen af derivater af 1-(2-halobiphenyl-4-yl)-cyclopropancarboxylsyre
DK2516359T3 (da) Fremgangsmåde til fremstilling af ethylbenzen
DK2462108T3 (da) Fremgangsmåde til fremstilling af pyrazolcarboxylsyreamider
DK2393795T3 (da) Fremgangsmåde til fremstilling af hydroxymethyldiphenyloxiraner og tilsvarende 1-azolylmethyl-1,2-diphenyloxiraner
DK2493860T3 (da) Fremgangsmåde til fremstilling af 4-sulfinylpyrazolderivater
DK2456747T3 (da) Fremgangsmåde til fremstilling af alkoxyenoner og enaminoketoner